Filing Flows

Filing Flows › Comparisons › INVA vs HROW

Innoviva vs Harrow: INVA and HROW compared

Innoviva is the larger company: $106M of revenue in its latest quarter (Q3 2026) against $99.3M for Harrow (Q3 2026). Harrow is growing faster (+39% against -2% a year earlier). Innoviva is more profitable, with an operating margin of 39.7% against 11.6%.

Innoviva vs Harrow, latest quarterInnoviva vs Harrow, latest quarterInnoviva (INVA)Harrow (HROW)Revenue$106M$99.3MRevenue growth, Y/Y-2%+39%Operating margin39.7%11.6%Net margin-69.6%9.8%

Where the money goes: INVA and HROW

Innoviva (INVA) · Q3 2026

Innoviva, Q3 2026: revenue $106M (-2% year over year), operating margin 39.7%, net loss $73.9M, operating cash flow $41.7M. The chart follows the revenue to costs, profit and cash.

Harrow (HROW) · Q3 2026

Harrow, Q3 2026: revenue $99.3M (+39% year over year), operating margin 11.6%, net earnings $9.8M. The chart follows the revenue to costs, profit and cash.

Innoviva revenue by segment, Q3 2026Innoviva revenue by segment, Q3 2026Royalty$54.7MProduct$49.4MLicense and Other Revenue$2.0M
Innoviva (INVA)Harrow (HROW)
Latest quarterQ3 2026Q3 2026
Revenue$106M$99.3M
Revenue growth, Y/Y-2%+39%
Gross margin—75.4%
Operating margin39.7%11.6%
Net earnings−$73.9M$9.8M
Net margin-69.6%9.8%
Operating cash flow$41.7M—
Free cash flow$41.7M—

Where the revenue comes from

Innoviva

Questions

Which is bigger, Innoviva or Harrow?

Innoviva is the larger company: $106M of revenue in its latest quarter (Q3 2026) against $99.3M for Harrow (Q3 2026).

Is Innoviva or Harrow growing faster?

Harrow is growing faster (+39% against -2% a year earlier).

Which is more profitable, Innoviva or Harrow?

Innoviva is more profitable, with an operating margin of 39.7% against 11.6%.

More: Innoviva earnings · how Innoviva makes money · Harrow earnings · how Harrow makes money

From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 8-K filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.